Stories about Krankheit

Helmholtz Munich

Engineering Smart Delivery for Gene Editors

Immunity Pharma

Immunity Pharma Presents New Data Supporting the Efficacy of IPL344 in ALS

Jerusalem (ots/PRNewswire) - - Results from phase 2a trial in ALS patients were published in Muscle and Nerve. - Statistically significant 58% to 64% slower ALSFRS-R progression rate in IPL344-treated patients compared to the matched PRO-ACT records. - NfL was reduced by 27% for patients treated for at least two months. - Unadjusted median survival for participants in ...

ARTTIC Innovation GmbH

SGLT2 HYPE: New EU-funded Project Aims to Transform Hypertension Treatment

Europäischer Rechnungshof - European Court of Auditors

(Pressinbjudan) Bidrog återhämtningsfonderna efter pandemin till bättre arbetsmarknader i EU-länderna?

Pressinbjudan till den 26 mars 2025 Bidrog återhämtningsfonderna efter pandemin till bättre arbetsmarknader i EU-länderna? - Presskonferens online onsdagen den 26 mars kl. 10.00 CET. - Offentliggörande samma dag kl. 17.00 ...

STADA Arzneimittel AG

3

Press Release STADA’s growth journey continues in 2024 - Significant increase in sales and profits - Growing ahead of the market

Grünenthal Group

Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal

Aachen, Germany & Toronto, Canada, (ots) - Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, ...

Helmholtz Munich

New Knowledge Portal Adiposetissue.org Enhances Obesity and Metabolism Research with Centralized Data

Norgine

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.

London (ots/PRNewswire) - Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare ...

Helmholtz Munich

Ancient Viral DNA Shapes Early Embryo Development

Over half of our genomes consists of thousands of remnants of ancient viral DNA, known as transposable elements, which are widespread across the tree of life. Once dismissed as the "dark side" of the genome, researchers at Helmholtz Munich and Ludwig-Maximilians-Universität (LMU) have now revealed their crucial role in early embryo development. Unanswered Questions About the Role of Ancient Viral DNA Transposable ...

Helmholtz Munich

SCP-Nano: A New Technology to Visualize Nanocarriers in Cells and Tissues

Bosch Healthcare Solutions GmbH

Vivalytic Bacterial Meningitis by Bosch: PCR rapid test for medical emergencies

BIAL SA

BIAL Announces First Patient Out in its Phase 2 Clinical Trial of BIA 28-6156 - a Novel Therapy for GBA1 Parkinson's Disease

Porto, Portugal (ots/PRNewswire) - BIAL, a hundred-year-old innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, announced that the first patient has completed the full dose regimen in the ACTIVATE Phase 2 study. BIA 28-6156 is a first-in-class, small molecule for once-daily oral ...

Norgine

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

London (ots/PRNewswire) - Back to media releases Next media release Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, in ...

RHEACELL GmbH und Co. KG

RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

Accord Healthcare

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®

London (ots/PRNewswire) - - Accord announces that the European Commission (EC has granted marketing authorisation for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immune medicated inflammatory diseases. - The EC approval follows a positive opinion issued on 19 October ...

Helmholtz Munich

Maria-Elena Torres-Padilla Honored With the Leibniz Prize 2025

Technische Universität München

Complex pancreatic tumor organoids as foundation for new treatment strategies

TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Foundation for new cancer treatment strategies Organoids represent the complex cell landscape of pancreatic cancer - Tumors are composed of cancer cells with a variety of different characteristics. - This contributes significantly to the complexity of pancreatic cancer and makes the disease difficult to treat. - For the ...

Obrist Group

Obrist Group Introduces Alternatives to PFAS and F-Gases

Obrist Group Introduces Alternatives to PFAS and F-Gases Natural Refrigerants Replacing Harmful Forever Chemicals in Cars Lindau/Germany, Lustenau/Austria – December 10 2024 – Per- and polyfluoroalkyl substances (PFAS) are recognized as highly hazardous, and the European Union is preparing to ban these toxic chemicals. The PFAS group also includes F-gases, such as hydrofluorocarbons, which are widely used in cooling ...

GEA Group Aktiengesellschaft

GEA launches Body Condition Scoring for cows

European Alliance Against Depression

First European Patient Congress Depression for those affected by depression and their close relations takes place online on December 7, 2024 / Free online-event offers information and experience-sharing

Frankfurt am Main (ots) - The European Patient Congress Depression, hosted by the European Alliance Against Depression (EAAD), will take place on December 7, 2024. This free online-event is designed to support individuals affected by depression and their relatives, providing a platform for expert guidance, patient ...

Helmholtz Munich

Inceptor Regulates Insulin Homeostasis: A New Approach for Diabetes Therapies

ARTTIC Innovation GmbH

Last Call for canSERV Third Open Call Funding

Grünenthal Group

Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain

Aachen, Germany/Morristown, N.J. (ots) - - The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures ...

Grünenthal Group

First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist

Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...